Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 198 for:    Venetoclax AND ABT-199

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03534323
Recruitment Status : Recruiting
First Posted : May 23, 2018
Last Update Posted : July 4, 2019
Sponsor:
Collaborator:
Verastem, Inc.
Information provided by (Responsible Party):
Matthew S. Davids, MD, Dana-Farber Cancer Institute

Brief Summary:
This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Drug: Duvelisib Drug: Venetoclax Phase 1 Phase 2

Detailed Description:

This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational drugs and also tries to define the appropriate dose of the investigational drugs to use for further studies. "Investigational" means that the drugs are being studied together for the first time.

This phase I study tests the safety of the drug duvelisib when used in combination with the drug venetoclax. Since duvelisib is still being studied, the FDA (the U.S. Food and Drug Administration) has not approved duvelisib as a treatment for any disease.

Duvelisib is a drug that is given in capsule form and taken by mouth. This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells. In laboratory studies and in other clinical trials that included participants with CLL, duvelisib was effective at killing CLL cells.

Venetoclax is a tablet that is taken by mouth. Venetoclax targets a protein called BCL-2, which helps cancer cells survive. Venetoclax is an effective treatment for many participants with CLL who do not respond to chemotherapy or other approved drugs or who have relapsed after prior therapy. Venetoclax is FDA approved for participants with CLL who have a genetic changes (called a deletion 17p abnormality) and have had their CLL worsen after at least one prior therapy for their CLL.

In the phase I portion of this study, the investigators are looking to determine the dose of venetoclax that is safe to give with duvelisib and to see what the side effects are of this combination.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 47 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Actual Study Start Date : July 12, 2018
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : June 1, 2024


Arm Intervention/treatment
Experimental: Duvelisib +Venetoclax,

Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.

  • Duvelisib will be administered orally twice daily
  • Venetoclax will be administered orally daily
  • All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation
Drug: Duvelisib
This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
Other Name: IPI-145

Drug: Venetoclax
Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
Other Name: Venclexta




Primary Outcome Measures :
  1. Maximum Tolerated Dose of Venetoclax When Administered with Duvelisib [ Time Frame: Up to 7 weeks ]
    As assessed by protocol-specified DLT criteria (phase I)

  2. Rate of complete remission [ Time Frame: 2 years ]
    By IW-CLL criteria (phase II)


Secondary Outcome Measures :
  1. Cmax [ Time Frame: Up to 7 weeks ]
    Cmax

  2. Half-life [ Time Frame: Up to 7 weeks ]
    Half-life

  3. Volume of Distribution [ Time Frame: Up to 7 weeks ]
    Volume of Distribution

  4. Objective response rate [ Time Frame: 2 years ]
    By IW-CLL Criteria

  5. Duration of response [ Time Frame: 2 years ]
    By IW-CLL Criteria

  6. Progression free survival [ Time Frame: 2 years ]
    By IW-CLL Criteria

  7. Rate of minimal residual disease negativity [ Time Frame: 2 years ]
    By IW-CLL Criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma requiring therapy, as per IW-CLL 2008 criteria
  • Disease that has progressed during or relapsed after at least one previous CLL/SLL therapy
  • Age greater to or equal to 18 years
  • ECOG performance status ≤2 (Karnofsky ≥60%)
  • Patients must meet the following hematologic criteria at screening, unless they have significant bone marrow involvement of CLL confirmed on biopsy:

    • Absolute neutrophil count ≥500 cells/mm3 (0.5 x 109/L). Growth factor is allowed in order to achieve this
    • Platelet count ≥25,000 cells/mm3 (25 x 109/L) independent of transfusion within 7 days of screening
  • Adequate hepatic function defined as:

    --Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN), bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin

  • Adequate renal function as defined as:

    --Serum creatinine ≤1.5 times the upper limit of normal or creatinine clearance ≥ 50 mL/min using a 24-hour urine collection

  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal, barrier method or abstinence) prior to study entry and for the duration of study participation
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Previous treatment with venetoclax or duvelisib
  • Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, surgery within 2 weeks of Cycle 1/Day 1 with the following exceptions:

    • For patients on targeted therapies, a washout of least five half lives is required
    • Patients who experience clinical deterioration may start therapy after a shorter washout period with prior approval by the PI
    • Corticosteroid therapy (prednisone or equivalent <20 mg daily) is allowed
  • Confirmed central nervous system involvement
  • Allogeneic hematologic stem cell transplant within 6 months of starting study treatment or active graft vs. host disease (GVHD) requiring treatment or prophylaxis
  • History of active malignancy requiring therapy with the exception of hormonal therapy
  • Any active systemic infection requiring IV antibiotics or uncontrolled, active infections
  • Known history of human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
  • Major surgery within 4 weeks of first dose of study drug
  • Currently active gastrointestinal disease, including colitis, inflammatory bowel disease and diarrhea requiring therapy
  • Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
  • Use of Coumadin for anticoagulation (other anticoagulants permitted)
  • Lactating or pregnant
  • Concurrent administration of medications or foods that are strong inhibitors or inducers of CYP3A (see Appendix D) . The concomitant use of drugs or foods that are strong or moderate inhibitors or inducers of CYP3A are not allowed beginning 1 week prior to the first dose of duvelisib.
  • Patients with ongoing use of prophylactic antibiotics are eligible as long as there is no evidence of active infection and the antibiotic is not included on the list of prohibited medications
  • Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction resulting in malabsorption or chronic diarrhea
  • Active abuse of alcohol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03534323


Contacts
Layout table for location contacts
Contact: Alexandra Savell 617-632-3539 asavell@partners.org

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Jacob Soumerai, MD    617-726-2865    jsoumerai@mgh.harvard.edu   
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Jon Arnason, MD    617-667-9920    jarnason@bidmc.harvard.edu   
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Matthew Davids, MD         
Contact: Alexandra Savell    617-632-3539    asavell@partners.org   
Principal Investigator: Matthew S Davids, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Verastem, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Matthew S Davids, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Matthew S. Davids, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03534323     History of Changes
Other Study ID Numbers: 18-089
First Posted: May 23, 2018    Key Record Dates
Last Update Posted: July 4, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Matthew S. Davids, MD, Dana-Farber Cancer Institute:
chronic lymphocytic leukemia (CLL)
Additional relevant MeSH terms:
Layout table for MeSH terms
Venetoclax
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Antineoplastic Agents